489 related articles for article (PubMed ID: 16764342)
1. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis.
Liuzzi GM; Trojano M; Fanelli M; Avolio C; Fasano A; Livrea P; Riccio P
Mult Scler; 2002 May; 8(3):222-8. PubMed ID: 12120694
[TBL] [Abstract][Full Text] [Related]
3. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
[TBL] [Abstract][Full Text] [Related]
4. TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis.
Trentini A; Manfrinato MC; Castellazzi M; Tamborino C; Roversi G; Volta CA; Baldi E; Tola MR; Granieri E; Dallocchio F; Bellini T; Fainardi E;
Mult Scler; 2015 Aug; 21(9):1121-30. PubMed ID: 25662349
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
7. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Paolino E; Tola MR; Granieri E; Baricordi OR
Mult Scler; 2006 Feb; 12(1):2-12. PubMed ID: 16459714
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis.
Castellazzi M; Tamborino C; Cani A; Negri E; Baldi E; Seraceni S; Tola MR; Granieri E; Contini C; Fainardi E
Mult Scler; 2010 Jul; 16(7):883-7. PubMed ID: 20483883
[TBL] [Abstract][Full Text] [Related]
10. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes.
Avolio C; Ruggieri M; Giuliani F; Liuzzi GM; Leante R; Riccio P; Livrea P; Trojano M
J Neuroimmunol; 2003 Mar; 136(1-2):46-53. PubMed ID: 12620642
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
12. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease.
Hamzaoui K; Maître B; Hamzaoui A
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S52-7. PubMed ID: 19796534
[TBL] [Abstract][Full Text] [Related]
14. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
Avolio C; Filippi M; Tortorella C; Rocca MA; Ruggieri M; Agosta F; Tomassini V; Pozzilli C; Stecchi S; Giaquinto P; Livrea P; Trojano M
Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
[TBL] [Abstract][Full Text] [Related]
15. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Waubant E; Goodkin D; Bostrom A; Bacchetti P; Hietpas J; Lindberg R; Leppert D
Neurology; 2003 Jan; 60(1):52-7. PubMed ID: 12525717
[TBL] [Abstract][Full Text] [Related]
16. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Yuceyar N; Taşkiran D; Sağduyu A
Clin Neurol Neurosurg; 2001 Dec; 103(4):206-11. PubMed ID: 11714562
[TBL] [Abstract][Full Text] [Related]
17. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
18. Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms.
Fainardi E; Castellazzi M; Tamborino C; Seraceni S; Tola MR; Granieri E; Contini C
J Neurovirol; 2009 Sep; 15(5-6):425-33. PubMed ID: 20053141
[TBL] [Abstract][Full Text] [Related]
19. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.
Waubant E; Goodkin DE; Gee L; Bacchetti P; Sloan R; Stewart T; Andersson PB; Stabler G; Miller K
Neurology; 1999 Oct; 53(7):1397-401. PubMed ID: 10534241
[TBL] [Abstract][Full Text] [Related]
20. Decreased MMP-9 production in primary progressive multiple sclerosis patients.
Sastre-Garriga J; Comabella M; Brieva L; Rovira A; Tintoré M; Montalban X
Mult Scler; 2004 Aug; 10(4):376-80. PubMed ID: 15327032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
